Caley Castelein
CIK 1355758 · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$10.92M
Companies
5
Total Filings
46
Lifetime Open-Market Net
$7.12M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WHWK | Director | 2,440,794 | $4.47 | $10.92M | $0 | 3 | 2026-06-15 |
| Tourmaline Bio, Inc. (TRML) Delisted | Director | 0 | $47.98 | $0 | $280.6K | 5 | 2025-10-28 |
| Whitehawk Therapeutics, Inc. (AADI) Delisted | Director | 2,185,692 | $2.05 | $4.48M | $3.40M | 6 | 2025-03-04 |
| ViewRay, Inc. (VRAY) Delisted | Director | 99,047 | $0.03 | $2.5K | $3.44M | 20 | 2023-07-21 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | Director | 19,694 | $33.00 | $649.9K | $0 | 6 | 2021-07-02 |
Recent Filings · Page 2 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-23 | — | Grant (A) | +954,558 | $0 | |
| 2023-07-21 | ViewRay, Inc. (VRAY) Delisted | Sell (S) | −2,345,030 | -$165.4K | EDGAR |
| 2023-07-19 | — | Notice (144) | −158,397 | -$10.8K | EDGAR |
| 2023-07-19 | — | Notice (144) | −1,545,600 | -$116.7K | EDGAR |
| 2023-07-19 | — | Notice (144) | −641,033 | -$56.7K | EDGAR |
| 2023-06-20 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-04 | ViewRay, Inc. (VRAY) Delisted | Grant (A) | +16,590 | $73.0K | EDGAR |
| 2022-09-27 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | +240,000 | $3.00M | EDGAR |
| 2022-06-17 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-15 | ViewRay, Inc. (VRAY) Delisted | Grant (A) | +54,511 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.